NCT04266353

Effect of Resveratrol on Serum IGF2 Among African American Women

Withdrawn NA Last updated 9 May 2023

What this trial tests

NA trial testing Resveratrol (RSV) in Chemoprevention. Withdrawn.

Timeline

24 April 2019

Primary endpoint
22 August 2022

22 August 2022

Quick facts

Lead sponsor	Loma Linda University
Phase	NA
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Start date	24 April 2019
Primary completion	22 August 2022
Estimated completion	22 August 2022
Sites	1 location across United States

Drugs / interventions tested

• Resveratrol (RSV)

Conditions studied

• Chemoprevention — all drugs for Chemoprevention →

Sponsor

Loma Linda University

Who can join

18 and older, female only, with Chemoprevention. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

African American (AA) women with breast cancer (BC) have higher mortality and are associated with worse outcomes when treated with available adjuvant treatments. Addressing this survival disparity will depend on identifying contributing biologic factors that can be translated into new treatments. Preclinical studies have shown that Insulin-like growth factor-II (IGF-II)expression was significantly higher in AA cell lines and tissue samples when compared to Caucasians indicating that IGF-II is an important biologic factor contributing to higher breast cancer mortality in AA women and is also responsible for chemoresistance in BC cells. In addition preclinical studies also demonstrated that resveratrol (RSV) inhibits IGF-II and induces apoptosis in BC cell lines. Researchers want to test IGF-II levels at baseline in healthy African American women and monitor levels while on resveratrol therapy for 6 weeks.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Plant-Derived Anticancer Compounds as New Perspectives in Drug Discovery and Alternative Therapy.
   Dehelean CA, Marcovici I, Soica C, Mioc M, et al · · 2021 · cited 244× · PMID 33669817 · DOI 10.3390/molecules26041109
2. Phytochemicals in Cancer Treatment and Cancer Prevention-Review on Epidemiological Data and Clinical Trials.
   Rudzińska A, Juchaniuk P, Oberda J, Wiśniewska J, et al · · 2023 · cited 89× · PMID 37111115 · DOI 10.3390/nu15081896
3. More Than Resveratrol: New Insights into Stilbene-Based Compounds.
   Pecyna P, Wargula J, Murias M, Kucinska M. · · 2020 · cited 87× · PMID 32726968 · DOI 10.3390/biom10081111
4. Natural Radiosensitizers in Radiotherapy: Cancer Treatment by Combining Ionizing Radiation with Resveratrol.
   Komorowska D, Radzik T, Kalenik S, Rodacka A. · · 2022 · cited 48× · PMID 36142554 · DOI 10.3390/ijms231810627
5. Antioxidants for the Treatment of Breast Cancer: Are We There Yet?
   Griñan-Lison C, Blaya-Cánovas JL, López-Tejada A, Ávalos-Moreno M, et al · · 2021 · cited 43× · PMID 33572626 · DOI 10.3390/antiox10020205
6. Resveratrol-Laden Nano-Systems in the Cancer Environment: Views and Reviews.
   Sarfraz M, Arafat M, Zaidi SHH, Eltaib L, et al · · 2023 · cited 17× · PMID 37760469 · DOI 10.3390/cancers15184499
7. A Review of Twenty Years of Research on the Regulation of Signaling Pathways by Natural Products in Breast Cancer.
   Naeem M, Iqbal MO, Khan H, Ahmed MM, et al · · 2022 · cited 16× · PMID 35684353 · DOI 10.3390/molecules27113412
8. Putative role of natural products as Protein Kinase C modulator in different disease conditions.
   Singh RK, Kumar S, Tomar MS, Verma PK, et al · · 2021 · cited 11× · PMID 34216003 · DOI 10.1007/s40199-021-00401-z